FATE THERAPEUTICS INC. - COMMON STOCK

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

04 فبراير 2025 16:01:00 بحسب Nasdaq GlobeNewswire

NetDania - New 12 months Low: FATE THERAPEUTICS INC. - COMMON STOCK

14 يناير 2025 09:45:18 بحسب NetDania Notify

NetDania - New 12 months Low: FATE THERAPEUTICS INC. - COMMON STOCK

13 يناير 2025 09:45:04 بحسب NetDania Notify

NetDania - New 12 months Low: FATE THERAPEUTICS INC. - COMMON STOCK

10 يناير 2025 10:22:09 بحسب NetDania Notify

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

03 يناير 2025 16:01:00 بحسب Nasdaq GlobeNewswire

NetDania - New 12 months Low: FATE THERAPEUTICS INC. - COMMON STOCK

30 ديسمبر 2024 09:52:19 بحسب NetDania Notify

NetDania - New 12 months Low: FATE THERAPEUTICS INC. - COMMON STOCK

26 ديسمبر 2024 13:03:48 بحسب NetDania Notify

NetDania - New 12 months Low: FATE THERAPEUTICS INC. - COMMON STOCK

23 ديسمبر 2024 10:24:21 بحسب NetDania Notify

NetDania - New 12 months Low: FATE THERAPEUTICS INC. - COMMON STOCK

19 ديسمبر 2024 10:10:18 بحسب NetDania Notify

NetDania - New 12 months Low: FATE THERAPEUTICS INC. - COMMON STOCK

18 ديسمبر 2024 09:46:00 بحسب NetDania Notify

NetDania - New 12 months Low: FATE THERAPEUTICS INC. - COMMON STOCK

13 ديسمبر 2024 09:45:20 بحسب NetDania Notify

NetDania - New 12 months Low: FATE THERAPEUTICS INC. - COMMON STOCK

12 ديسمبر 2024 10:17:16 بحسب NetDania Notify

Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus

09 ديسمبر 2024 16:01:00 بحسب Nasdaq GlobeNewswire

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

03 ديسمبر 2024 16:01:00 بحسب Nasdaq GlobeNewswire

Fate Therapeutics Announces Leadership Transition

29 نوفمبر 2024 13:05:00 بحسب Nasdaq GlobeNewswire

Fate Therapeutics to Present at Upcoming December Investor Conferences

26 نوفمبر 2024 16:01:00 بحسب Nasdaq GlobeNewswire

Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence

18 نوفمبر 2024 08:05:00 بحسب Nasdaq GlobeNewswire

Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence

18 نوفمبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

NetDania - New 12 months Low: FATE THERAPEUTICS INC. - COMMON STOCK

15 نوفمبر 2024 09:46:29 بحسب NetDania Notify

NetDania - New 12 months Low: FATE THERAPEUTICS INC. - COMMON STOCK

14 نوفمبر 2024 09:54:48 بحسب NetDania Notify